Tesofensine/metoprolol - Saniona

Drug Profile

Tesofensine/metoprolol - Saniona

Alternative Names: metoprolol/tesofensine; Tesomet

Latest Information Update: 31 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Saniona
  • Class Antihyperglycaemics; Chlorobenzenes; Heterocyclic bicyclo compounds; Obesity therapies; Propanolamines; Small molecules
  • Mechanism of Action Beta 1 adrenergic receptor antagonists; Biogenic monoamine uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Prader-Willi syndrome; Type 2 diabetes mellitus

Most Recent Events

  • 26 Oct 2017 Efficacy and adverse events data from a phase IIa trial in Prader-Willi syndrome released by Saniona
  • 22 Sep 2017 Saniona plans a phase I trial in Healthy volunteers in Germany (NCT03286829)
  • 11 Sep 2017 Adverse events and efficacy data from a phase II trial in Type 2 diabetes mellitus presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top